UPDATED RESULTS OF A PHASE II STUDY OF LENALIDOMIDE AND RITUXIMAB IN RELAPSED/REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA.

被引：0
|
作者：
Piris-Villaespesa, M. [1 ]
Chavez, J. [2 ]
Dalia, S. [2 ]
Veliz, M. [3 ]
Lancet, Jeffrey [2 ]
Bello, C. [2 ]
Turba, E. [2 ]
Shah, B. [2 ]
Komrokji, R. [2 ]
Sokol, L. [2 ]
Locke, F. [4 ]
Kharfan-Dabaja, M. [4 ]
Sotomayor, E. [2 ]
Pinilla-Ibarz, J. [2 ]
机构：
[1] Hosp Univ Puerta de Hierro Majadahonda, Hematol, Madrid, Spain
[2] H Lee Moffitt Canc Ctr & Res Inst, Malignant Hematol, Tampa, FL USA
[3] Cent Florida Hematol Onc, Hematol, Tampa, FL USA
[4] H Lee Moffitt Canc Ctr & Res Inst, Bone Marrow Transplant, Tampa, FL USA
来源：
HAEMATOLOGICA | 2013年 / 98卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P108
引用
收藏
页码：46 / 46
页数：1
相关论文
共 50 条
  • [31] A phase II, open label study of AT-101 in combination with rituximab in patients with relapsed or refractory chronic lymphocytic leukemia. Evaluation of two dose regimens
    Castro, Januario E.
    Loria, Olivier J.
    Aguillon, Robier A.
    James, Danelle
    Llanos, Cesar A.
    Rassenti, Laura
    Wood, Brian A.
    Homlund, Jon T.
    Kipps, Thomas J.
    BLOOD, 2007, 110 (11) : 917A - 918A
  • [32] Lenalidomide active in patients with refractory or relapsed chronic lymphocytic leukemia
    Nature Clinical Practice Oncology, 2007, 4 (3): : 143 - 143
  • [33] Phase 2 Study of Acalabrutinib in Ibrutinib-Intolerant Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)
    Rogers, Kerry A.
    Thompson, Philip A.
    Allan, John N.
    Coleman, Morton
    Sharman, Jeff P.
    Cheson, Bruce D.
    Izumi, Raquel
    Frigault, Melanie M.
    Quah, Cheng
    Raman, Rakesh K.
    Wang, Min Hui
    Kipps, Thomas J.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S282 - S283
  • [34] ABT-199 (GDC-0199) COMBINED WITH RITUXIMAB (R) IN PATIENTS (PTS) WITH RELAPSED / REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): INTERIM RESULTS OF A PHASE 1B STUDY
    Roberts, A. W.
    Ma, S.
    Kipps, T.
    Barrientos, J. C.
    Davids, M. S.
    Anderson, M. A.
    Tam, C.
    Mason-Bright, T.
    Rudersdorf, N. K.
    Yang, J.
    Munasinghe, W.
    Zhu, M.
    Cerri, E.
    Enschede, S. H.
    Humerickhouse, R. A.
    Seymour, J. F.
    HAEMATOLOGICA, 2014, 99 : 249 - 249
  • [35] Rituximab® and high dose methylprednisolone (HDMP) for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia.
    Castro, JE
    Bole, J
    Prada, CE
    Kipps, TJ
    BLOOD, 2004, 104 (11) : 690A - 690A
  • [36] Acalabrutinib vs Rituximab Plus Idelalisib (IdR) or Bendamustine (BR) by Investigator Choice in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia: Phase 3 ASCEND Study
    Ghia, Paolo
    Pluta, Andrzej
    Wach, Malgorzata
    Lysak, Daniel
    Kozak, Tomas
    Simkovic, Martin
    Kaplan, Polina
    Kraychok, Iryna
    Illes, Arpad
    De La Serna, Javier
    Dolan, Sean
    Campbell, Phillip
    Musuraca, Gerardo
    Jacob, Abraham
    Avery, Eric J.
    Lee, Jae Hoon
    Liang, Wei
    Patel, Priti
    Quah, Cheng
    Jurczak, Wojciech
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S280 - S281
  • [37] Acalabrutinib (Acala) vs Idelalisib plus Rituximab (IdR) or Bendamustine plus Rituximab (BR) in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): ASCEND final results
    Welslau, M.
    Ghia, P.
    Pluta, A.
    Wach, M.
    Lysak, D.
    Kozak, T.
    Simkovic, M.
    Kaplan, P.
    Kraychok, I
    Illes, A.
    de la Serna, J.
    Dolan, S.
    Campbell, P.
    Musuraca, G.
    Jacob, A.
    Avery, E. J.
    Lee, J. H.
    Wang, D.
    Patel, P.
    Quah, C.
    Jurczak, W.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 71 - 72
  • [38] Acalabrutinib (Acala) vs Idelalisib plus Rituximab (IdR) or Bendamustine plus Rituximab (BR) in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): ASCEND Final Results
    Jacob, Abraham
    Ghia, Paolo
    Pluta, Andrzej
    Wach, Malgorzata
    Lysak, Daniel
    Kozak, Tomas
    Simkovic, Martin
    Kaplan, Polina
    Kraychok, Iryna
    Illes, Arpad
    De La Serna, Javier
    Dolan, Sean
    Campbell, Philip
    Musuraca, Gerardo
    Avery, Eric Joseph
    Lee, Jae Hoon
    Wang, Denise
    Patel, Priti
    Quah, Cheng Seok
    Jurczak, Wojciech
    BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 : 141 - 142
  • [39] A phase II study of the combination of lenalidomide and rituximab as frontline treatment in patients with chronic lymphocytic leukemia
    Strati, Paolo
    Thompson, Philip
    Keating, Michael
    Hinojosa, Christina
    Rodriguez, Diana
    Jain, Nitin
    Burger, Jan A.
    Estrov, Zeev
    O'Brien, Susan
    Wierda, William
    Ferrajoli, Alessandra
    LEUKEMIA & LYMPHOMA, 2017, 58 : 70 - 72
  • [40] LLC-LENAR-08 A PHASE I/II STUDY LENALIDOMIDE-RITUXIMAB IN RELAPSE/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
    De La Fuente, A.
    Gonzalez, M.
    Giraldo, P.
    de la Cruz, F.
    Terol, M. J.
    Perez Simon, J. A.
    Rodriguez, G.
    Montalban, C.
    Toas, J. F.
    de Ona, R.
    HAEMATOLOGICA, 2015, 100 : 55 - 55
12345